$2.14 Billion is the total value of Tekla Capital Management LLC's 96 reported holdings in Q4 2014. The portfolio turnover from Q3 2014 to Q4 2014 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ACOR | Exit | Acorda Therapeutics, Inc.call | $0 | – | -47,400 | -100.0% | -0.08% | – |
| THOR | Exit | Thoratec Corporation | $0 | – | -113,300 | -100.0% | -0.14% | – |
| ALGN | Exit | Align Technology, Inc. | $0 | – | -70,400 | -100.0% | -0.17% | – |
| TEVA | Exit | Teva Pharmaceutical Industries Ltd.call | $0 | – | -68,600 | -100.0% | -0.17% | – |
| EPZM | Exit | Epizyme, Inc. | $0 | – | -141,262 | -100.0% | -0.18% | – |
| ILMN | Exit | Illumina, Inc.call | $0 | – | -23,600 | -100.0% | -0.18% | – |
| NKTR | Exit | Nektar Therapeuticscall | $0 | – | -334,800 | -100.0% | -0.19% | – |
| NKTR | Exit | Nektar Therapeutics | $0 | – | -334,800 | -100.0% | -0.19% | – |
| P103PS | Exit | NPS Pharmaceuticals, Inc.call | $0 | – | -156,000 | -100.0% | -0.19% | – |
| BIIB | Exit | Biogen Idec, Inc.call | $0 | – | -12,800 | -100.0% | -0.20% | – |
| BLUE | Exit | bluebird Bio, Inc.call | $0 | – | -118,400 | -100.0% | -0.20% | – |
| MYGN | Exit | Myriad Genetics, Inc.call | $0 | – | -112,200 | -100.0% | -0.20% | – |
| NBIX | Exit | Neurocrine Biosciences, Inc.call | $0 | – | -281,600 | -100.0% | -0.21% | – |
| ALXN | Exit | Alexion Pharmaceuticals, Inc.call | $0 | – | -26,800 | -100.0% | -0.21% | – |
| INCY | Exit | Incyte Corporationcall | $0 | – | -93,500 | -100.0% | -0.22% | – |
| AMRN | Exit | Amarin Corporation plcsponsored adr | $0 | – | -5,643,412 | -100.0% | -0.29% | – |
| CLDX | Exit | Celldex Therapeutics, Inc.call | $0 | – | -508,400 | -100.0% | -0.31% | – |
| CLDX | Exit | Celldex Therapeutics, Inc. | $0 | – | -508,400 | -100.0% | -0.31% | – |
| UNH | Exit | UnitedHealth Group, Inc. | $0 | – | -83,186 | -100.0% | -0.34% | – |
| PKI | Exit | PerkinElmer, Inc. | $0 | – | -165,495 | -100.0% | -0.34% | – |
| SRPT | Exit | Sarepta Therapeutics Inc.call | $0 | – | -345,400 | -100.0% | -0.34% | – |
| IPXL | Exit | Impax Laboratories, Inc.call | $0 | – | -322,600 | -100.0% | -0.36% | – |
| CELG | Exit | Celgene Corporationcall | $0 | – | -180,800 | -100.0% | -0.80% | – |
| CBST | Exit | Cubist Pharmaceuticals, Inc. | $0 | – | -494,454 | -100.0% | -1.54% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-01-30
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Gilead Sciences, Inc. | 41 | Q2 2023 | 12.4% |
| Amgen, Inc. | 41 | Q2 2023 | 5.8% |
| Biogen Inc. | 41 | Q2 2023 | 6.5% |
| Vertex Pharmaceuticals Incorporated | 41 | Q2 2023 | 5.3% |
| Regeneron Pharmaceuticals, Inc. | 41 | Q2 2023 | 9.1% |
| Illumina, Inc. | 41 | Q2 2023 | 3.4% |
| BioMarin Pharmaceutical Inc. | 41 | Q2 2023 | 2.9% |
| Teva Pharmaceutical Industries Ltd. | 41 | Q2 2023 | 3.2% |
| Neurocrine Biosciences, Inc. | 41 | Q2 2023 | 1.4% |
| McKesson Corporation | 41 | Q2 2023 | 2.2% |
View Tekla Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rallybio Corp | January 23, 2023 | 1,727,067 | 4.6% |
| Zyla Life SciencesSold out | January 29, 2021 | 0 | 0.0% |
| ARCA biopharma, Inc. | January 24, 2020 | 36,068 | 2.3% |
| Verona Pharma plc | February 12, 2019 | 5,296,845 | 4.9% |
| Alliqua BioMedical, Inc. | February 12, 2018 | 165,000 | 3.3% |
| PIERIS PHARMACEUTICALS, INC. | February 12, 2018 | 1,962,380 | 4.4% |
| Intellipharmaceutics International Inc. | February 13, 2015 | 2,184,000 | 9.0% |
| HERON THERAPEUTICS, INC. /DE/ | February 14, 2014 | 20,598,613 | 4.2% |
| MEDWAVE INC | February 14, 2012 | 1,277,372 | 9.8% |
| MZT Holdings, Inc. | February 14, 2012 | 2,553,420 | 4.0% |
View Tekla Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-10 |
| SC 13G/A | 2023-01-23 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-29 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| SC 13G | 2022-01-21 |
| 13F-HR | 2021-11-12 |
View Tekla Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.